BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32675593)

  • 1. The role of myeloid-derived suppressor cells in hematologic malignancies.
    Gunes EG; Rosen ST; Querfeld C
    Curr Opin Oncol; 2020 Sep; 32(5):518-526. PubMed ID: 32675593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.
    Palumbo GA; Parrinello NL; Giallongo C; D'Amico E; Zanghì A; Puglisi F; Conticello C; Chiarenza A; Tibullo D; Raimondo FD; Romano A
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting myeloid-derived suppressor cells for cancer immunotherapy.
    Liu Y; Wei G; Cheng WA; Dong Z; Sun H; Lee VY; Cha SC; Smith DL; Kwak LW; Qin H
    Cancer Immunol Immunother; 2018 Aug; 67(8):1181-1195. PubMed ID: 29855694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of the Exosomes Derived From Myeloid-Derived Suppressor Cells in Tumor Immunity and Cancer Progression.
    Chen Z; Yuan R; Hu S; Yuan W; Sun Z
    Front Immunol; 2022; 13():817942. PubMed ID: 35154134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation.
    Yang Y; Li C; Liu T; Dai X; Bazhin AV
    Front Immunol; 2020; 11():1371. PubMed ID: 32793192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer.
    Li K; Shi H; Zhang B; Ou X; Ma Q; Chen Y; Shu P; Li D; Wang Y
    Signal Transduct Target Ther; 2021 Oct; 6(1):362. PubMed ID: 34620838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid-derived suppressor cells-new and exciting players in lung cancer.
    Yang Z; Guo J; Weng L; Tang W; Jin S; Ma W
    J Hematol Oncol; 2020 Jan; 13(1):10. PubMed ID: 32005273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.
    Groth C; Hu X; Weber R; Fleming V; Altevogt P; Utikal J; Umansky V
    Br J Cancer; 2019 Jan; 120(1):16-25. PubMed ID: 30413826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment.
    Qu P; Wang LZ; Lin PC
    Cancer Lett; 2016 Sep; 380(1):253-6. PubMed ID: 26519756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.
    Nakamura K; Smyth MJ
    Cell Mol Immunol; 2020 Jan; 17(1):1-12. PubMed ID: 31611651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies.
    Wang S; Zhao X; Wu S; Cui D; Xu Z
    Biomark Res; 2023 Mar; 11(1):34. PubMed ID: 36978204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
    Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
    Front Immunol; 2020; 11():585214. PubMed ID: 33613512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic Regulation of Myeloid-Derived Suppressor Cell Function in Cancer.
    Wang Y; Jia A; Bi Y; Wang Y; Liu G
    Cells; 2020 Apr; 9(4):. PubMed ID: 32325683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
    Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
    J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CCAAT/Enhancer-Binding Protein Family: Its Roles in MDSC Expansion and Function.
    Wang W; Xia X; Mao L; Wang S
    Front Immunol; 2019; 10():1804. PubMed ID: 31417568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid-derived suppressor cells as effectors of immune suppression in cancer.
    Pyzer AR; Cole L; Rosenblatt J; Avigan DE
    Int J Cancer; 2016 Nov; 139(9):1915-26. PubMed ID: 27299510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
    Alissafi T; Hatzioannou A; Mintzas K; Barouni RM; Banos A; Sormendi S; Polyzos A; Xilouri M; Wielockx B; Gogas H; Verginis P
    J Clin Invest; 2018 Aug; 128(9):3840-3852. PubMed ID: 29920188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Brief: Myeloid-derived suppressor cells in cancer.
    Solito S; Pinton L; Mandruzzato S
    J Pathol; 2017 May; 242(1):7-9. PubMed ID: 28097660
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment.
    Zhou J; Shen Q; Lin H; Hu L; Li G; Zhang X
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):329-336. PubMed ID: 30426212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients.
    Safarzadeh E; Mohammadi A; Mansoori B; Duijf PHG; Hashemzadeh S; Khaze V; Kazemi T; Derakhshani A; Silvestris N; Baradaran B
    Front Immunol; 2020; 11():613215. PubMed ID: 33679700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.